arrow
R

Ruchi P. Patel

Center for Cellular Immunotherapies
H指数:9
被引数:368

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) – design and rationale

一项关于sacituzumab govitecan联合或不联合atezolizumab治疗罕见泌尿生殖系统肿瘤(SMART)的2期研究——设计与原理

2025-06-230
PRE
CD5 deletion enhances the antitumor activity of adoptive T cell therapies

CD5缺失增强过继性T细胞疗法的抗肿瘤活性

2024-07-195
PRE
The BTLA–HVEM axis restricts CAR T cell efficacy in cancer
2024-06-030
PRE
Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing

制造过程中嵌合抗原受体T细胞浓度,大小,活力和双色表型的简化测量

2024-05-010
PRE
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

靶向CD19近膜域的新型anti-CD19嵌合抗原受体T细胞产品对非霍奇金淋巴瘤的安全性和有效性: 一项首次人体研究

2023-12-098
OAAI
An open label, dose escalation, phase 1 study of AT101, a novel CD19-directed CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma

在复发或难治性b细胞非霍奇金淋巴瘤患者中,针对CD19近膜表位的新型CD19-directed car-t细胞疗法AT101的开放标签,剂量递增,1期研究

2023-04-140
PRE
Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer
2022-07-2944
OA